Answers are grounded in this paper and cite their sources.
Review reveals potential of mRNA cancer vaccines in oncology, demonstrating successful global trials and regulatory insights in Russia.
Malignant neoplasms remain one of the leading causes of death worldwide, continuously driving the development and active implementation of new innovative treatments into clinical practice. This article provides a comprehensive review of the current status and prospects for the application of mRNA technologies in oncology, analyzing global clinical trial experience, the mechanism of action of therapeutic mRNA cancer vaccines, manufacturing processes, and the regulatory framework for the introduction of individual biotechnologically modified drugs (iBTMD) in the Russian Federation.
No takes yet. Share an insight, caveat, or question.
Bagdasarova et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: